[CAS NO. 104146-53-4] Cefditorensodium

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [104146-53-4]

Catalog

HY-17452

Brand

MCE

CAS

104146-53-4

DESCRIPTION [104146-53-4]

Overview

MDL	-
Molecular Weight	528.56
Molecular Formula	C19H17N6NaO5S3
SMILES	O=C(C1=C(/C=C\C2=C(N=CS2)C)CS[C@@]([C@@H]3NC(/C(C4=CSC(N)=N4)=N\OC)=O)([H])N1C3=O)O[Na]

For research use only. We do not sell to patients.

Summary

Cefditoren sodium (ME 1206) is a broad-spectrum, third-generation, oral cephalosporin antibacterial with enhanced stability against many common β lactamases. Cefditoren sodium has activity against Gram-negative organisms and Gram-positive organisms. Cefditoren sodium can be used in the research of infection diseases such as acute exacerbations of chronic bronchitis, community-acquired pneumonia (CAP), streptococcal pharyngitis/tonsillitis, or uncomplicated skin and skin structure infections ^[1] ^[2] .

In Vitro

Cefditoren (sodium) shows good activity against pneumoniae , S. pyogenes , Staphylococcus aureus , H. influenzae and H. parainfluenzae , M. catarrhalis ^[1] .

Organism	MIC50 (mg/L)	MIC90 (mg/L)	susceptible (%)
Gram-positive organisms
Streptococcus pneumoniae (untyped) ^a	0.015-0.25	0.12-1
PS	≤0.008-0.03	0.015-0.25	99-100
PI	0.06-0.5	0.25-0.5	94-100
PR	0.25-1	0.5-2	7-100
S. pyogenes	≤0.008-0.03	0.015-0.03	100
Staphylococcus aureus (MS)	0.12-0.5	0.5-1	50-100
Gram-negative organisms
Haemophilus	≤0.008-≤0.03	0.015-0.13
influenzae (untyped) ^b
β-Lactamase +	≤0.008-0.03	0.015-0.06	100
β-Lactamase -	≤0.008-0.03	0.015-0.06	100
H. parainfluenzae ^b	≤0.03	0.06
Moraxella	0.03-0.5	0.25-1	96
catarrhalis (untyped) ^b
β-Lactamase +	≤0.03-0.25	0.12-0.5	100
β-Lactamase -	≤0.008-0.03	0.015-0.06	100

^a Including PS, PI and PR strains.
^b Including both β-lactamase-positive and -negative strains.
MIC _50/90 =mean minimum inhibitory concentrations required to inhibit the growth of 50% or 90% of bacterial strains; MS =susceptible to meticillin; PI =intermediate susceptibility to penicillin; PR =resistant to penicillin; PS =susceptible to penicillin.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Pharmacokinetics in mice ^[1] ：

Cefditoren (mg/kg)	C ₀ (µg/ml)	t1/2 (h)	AUC _last (µg× h/ml)	T _last (h)
6.25	53.0	0.9	30.4	6
12.5	168.4	1.1	64.1	8
25	232.5	0.9	101.3	8
50	290.6	1.1	124.4	8

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT04709172	Meiji Pharma Spain S.A.	COVID-19 Pneumonia	January 5, 2021	Phase 4
NCT01553006	Thammasat University	Rhinosinusitis	January 2012	Phase 4
NCT00598403	Tedec-Meiji Farma, S.A.	Urinary Tract Infections	November 2007	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 31.25 mg/mL ( 59.12 mM ; ultrasonic and warming and heat to 60°C)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.8919 mL	9.4597 mL	18.9193 mL
5 mM	0.3784 mL	1.8919 mL	3.7839 mL
10 mM	0.1892 mL	0.9460 mL	1.8919 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (4.73 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (4.73 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-3-[(1Z)-2-(4-methyl-5-thiazolyl)ethenyl]-8-oxo-, sodium salt (1:1), (6R,7R)-

5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[2-(4-methyl-5-thiazolyl)ethenyl]-8-oxo-, monosodium salt, [6R-[3(Z),6α,7β(Z)]]-

5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2Z)-(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-3-[(1Z)-2-(4-methyl-5-thiazolyl)ethenyl]-8-oxo-, monosodium salt, (6R,7R)-

ME 1206

Cefditoren sodium